Per Sandén

Bleeding complications and mortality in warfarin-treated VTE patients, dependence of INR variability and iTTR

A. Själander, P. Svensson, H. Renlund, 2016, Thrombosis and Haemostasis.

Bleeding complications in venous thrombosis patients on well-managed warfarin

A. Själander, P. Svensson, H. Renlund, 2016, Journal of Thrombosis and Thrombolysis.

Soluble angiotensin‐converting enzyme 2 is transiently elevated in COVID‐19 and correlates with specific inflammatory and endothelial markers

F. V. von Meijenfeldt, S. Havervall, C. Thålin, 2021, medRxiv.

Warfarin treatment complications do not correlate to cTTR when above 70.

A. Själander, P. Svensson, H. Renlund, 2015, Thrombosis research.

Editorial: Platelet Function in COVID-19

I. Mitroulis, P. V. D. van der Meijden, A. Lundström, 2022, Frontiers in Cardiovascular Medicine.

Venous thromboembolism and cancer risk

A. Själander, P. Svensson, Per Sandén, 2016, Journal of Thrombosis and Thrombolysis.

Efficacy and safety of warfarin treatment in venous thromboembolic disease

Per Sandén, 2017 .

Warfarin treatment quality is consistently high in both anticoagulation clinics and primary care setting in Sweden.

Fredrik Björck, A. Själander, P. Svensson, 2015, Thrombosis research.